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Abstract
Mutations in RAB39B are a known cause of X-linked early onset Parkinson's disease. Isogenic human
embryonic stem cell lines carrying two independent deletions of RAB39B were generated using CRISPR/
Cas9 genome editing tool. The deletions were confirmed by PCR and direct sequence analysis in two edited
stem cell lines. Both cell lines showed pluripotency and displayed a normal karyotype. Further, they were able
to form embryoid bodies in vitro, and express markers indicative of differentiation to the three germ layers.
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Mutations in RAB39B are a known cause of X-linked early onset Parkinson's disease. Isogenic human embryonic
stem cell lines carrying two independent deletions of RAB39Bwere generated using CRISPR/Cas9 genome editing
tool. The deletions were confirmed by PCR and direct sequence analysis in two edited stem cell lines. Both cell
lines showed pluripotency and displayed a normal karyotype. Further, they were able to form embryoid bodies
in vitro, and express markers indicative of differentiation to the three germ layers.
© 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Resource Table:
1. Resource utility
The isogenic human embryonic stem cell (hESC) lines generated are
valuable models for studying the pathogenic mechanisms underlying
disease.
1.1. Resource details
Mutations in RAB39B are a cause of X-linked early onset Parkinson's
disease (PD) (Wilson et al., 2014; Mata et al., 2015; Lesage et al., 2015;
Shi et al., 2016). We generated isogenic hESC lines with a deletion of
RAB39B tomodel this genetic form of PD. These lineswill facilitate a bet-
ter understanding of the pathogenesis of PD, in addition to improved
understanding of the function of RAB39B and its therapeutic potential
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⁎ Corresponding author at: Associate Professor Paul J. Lockhart, Murdoch Children's
Research Institute, 50 Flemington Road Parkville, Victoria, 3052, Australia.
E-mail address: paul.lockhart@mcri.edu.au (P.J. Lockhart).
Unique stem cell lines identifier SCSe001-A-1/MCRIe002-A-1;
SCSe001-A-2/MCRIe002-A-2
Alternative names of stem cell lines MEL-1 10.2;
MEL-1 30.3
Institution Murdoch Children's Research Institute
Contact information of distributor paul.lockhart@mcri.edu.au
Type of cell lines ESC
Origin Human
Cell Source N/A
Clonality Clonal
Method of reprogramming N/A
Multiline rationale Isogenic clones
Gene modification Yes
Type of modification Gene deletion
Associated disease Parkinson's Disease
Gene/locus RAB39B/Xq28
Method of modification CRISPR/CAS9
Name of transgene or resistance N/A
Inducible/constitutive system N/A
Date archived/stock date October 2017
Cell line repository/bank The parental cell line MEL-1 (SCSe001-A)
is listed on the NIH Human Embryonic
(continued)
Unique stem cell lines identifier SCSe001-A-1/MCRIe002-A-1;
SCSe001-A-2/MCRIe002-A-2
Stem Cell Registry (NIH approval number
NIHhESC-11-0139).
Ethical approval This study was approved by the ethics
committee of the Royal Children's
Hospital (HREC 28097).
https://doi.org/10.1016/j.scr.2018.02.015
1873-5061/© 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
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in PD. The parental male hESC lineMEL-1 (SCSe001-A) was utilised and
the deletions were generated using two CRISPR guides targeted to ei-
ther exon 1 or 2 of RAB39B (Table 3). Two of eight independent single
colonies isolated were selected for further analysis based on cell mor-
phology and successful genome editing, MEL-1 10.2 and MEL-1 30.3.
Both hESC lines displayed a typical hESC morphology consistent with
the unmodified parental line, including small and tightly packed cells,
high nucleus to cytoplasm ratio and a prominent nucleoli (Fig. 1A, B,
scale bar = 100 μM). Successful deletion of RAB39B was confirmed by
PCR analysis. Further, Sanger sequencing analysis showed a 5 base
pair deletion in exon 1 of RAB39B in MEL-1 10.2 (NM_171998.3:
c.82_86del, p.Phe28Argfs*9), and a 148 base pair deletion spanning
exons 1 and 2 of RAB39B in MEL-1 30.3 (NM_171998.3: c.87_234del,
p.Glu30Thrfs*5) (Fig. 1C). The expression of pluripotency markers
OCT4A, SOX2 and NANOG, were verified by immunofluorescence stain-
ing (Fig. 1D, E, scale bar = 50 μM). Further, flow cytometry analysis
utilising the markers SSEA-4, CD9 and EPCAM was performed to quan-
tify pluripotent cells. Mouse embryonic fibroblast (MEF) feeders nega-
tive for these pluripotent markers were present in the cultures, and
were thus utilised in gating. N80% of viable cells sorted were positive
Fig. 1. Characterization of RAB39B-knockout pluripotent stem cells.
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for both SSEA-4 and EPCAM expression, and for both CD9 and EPCAM
expression (Fig. 1F, G). The hESC lines formed embryoid bodies
in vitro, which expressed markers consistent with development of the
three germ layers. This included SOX17 marking endoderm, Brachyury
marking mesoderm and PAX6 marking ectoderm development
(Fig. 1H, I, scale bar = 20 μM). In addition, the derived hESC RAB39B
mutant lines (MEL-1 10.2 and MEL-1 30.3) showed a normal karyotype
(46, XY) and an identical genotype with the parental MEL-1 cell line
when analysed by array comparative genomic hybridisation (SNP
array) confirming no alterations in genomic integrity during editing.
In conclusion, we report the generation and characterization of novel
stem cell models for RAB39B-mediated PD, which can be differentiated
into neuronal models to study the pathogenic mechanisms underlying
PD. (See Tables 1 and 2.)
2. Materials and methods
2.1. Genome editing of hESC
To genetically modify the hESC line SCSe001-A (MEL-1), cells were
transfected with two CRISPR guides targeted to RAB39B (Table 3) by
electroporation, using theNeon transfection system (Life Technologies).
Briefly, ~1 × 106 cells were harvested for electroporation, after which
the cells were immediately plated down onto MEF-coated plates in
hESCmedium containing DMEM/F12media (Gibco/Invitrogen) supple-
mentedwith 20% knockout serum replacer (Gibco/Invitrogen), 1× non-
essential amino acids (Gibco/Invitrogen), 1× GlutaMAX-I (Gibco/
Invitrogen), 1 × 2-Mercaptoethanol (Gibco/Invitrogen) and 10 ng/ml
basic fibroblast growth factor (PeproTech). After recovering for
2–3 days, the cells were single cell sorted into 96 well plates on the
basis of GFP expression, expression ofwhichwas associatedwithuptake
of the CRISPR guide expressing vectors (Ran et al., 2013). At ~2 weeks
single hESC colonies began to appear and were picked for expansion
and genotyping. Subsequently, successfully edited hESC lines were con-
verted to feeder free bulk culture on plates coated with Vitronectin
(Stemcell technologies), in E8medium (Stemcell technologies) for con-
tinued culture. All cells were cultured at 37 °C with 10% CO2.
2.2. cDNA synthesis and genotyping
Total RNA for cDNA synthesis was extracted from hESC pellets using
the SV Total RNA Isolation System according to manufacturer's instruc-
tions (Promega). cDNA was synthesized using the Transcriptor First
Strand cDNA Synthesis Kit according to manufacturer's instructions
(Roche). For genotyping, DNA was amplified using MyTaq DNA poly-
merase (Bioline) using specified primers (Table 3).
2.3. Immunofluorescence (IF)
hESCwere cultured on sterilized glass coverslips for IF analysis. Cells
werefixedwith4%Paraformaldehyde (PFA) for 10min at room temper-
ature, permeabilized in 0.2% Triton™ X-100 (Sigma) for 10min at room
temperature, and blocked in 20% Goat Serum (Life Technologies) for
60 min at room temperature. Cells were then incubated with primary
antibodies at 4 °C overnight, followed by secondary antibodies for
60 min at room temperature (Table 3). The coverslips were mounted
on slides with mounting media containing DAPI (VectorLabs). Images
were captured with AXIO Imager M1 light microscope and Axiocam
MRm camera (Carl-Zeiss).
2.4. Flow cytometry (FACs) analysis
hESCwere harvested and filtered through a cell-strainer cap fettle to
a FACs tube. Cells were then incubated with primary antibodies for
15 min on ice (Table 3), and stained with Propidium Iodide (Sigma)
prior to acquisition (LSRFortessa, BD Bioscience).
Table 2
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Fig. 1A, B
Phenotype Qualitative analysis
(Immunofluorescence)
OCT4A, NANOG, SOX2 Fig. 1D, E
Quantitative analysis
(Flow cytometry)
SSEA-4, CD9, Ep-CAM Fig. 1F, G
Genotype Karyotype
(SNP array)
arr(1−22)×2,(XY)×1
Resolution 0.50 Mb
Submitted in archive
with journal
Identity Genetic analysis SNPduo comparative analysis performed to compare parental and both derived clones Submitted in archive
with journal
Identical genotypes (N99.9%) for the entire genome, indicating derived cell lines are
from the same individual
Submitted in archive
with journal
Mutation analysis (IF
APPLICABLE)
Sequencing
(PCR)
MEL-1 10.2 (NM_171998.3: c.82_86del)
MEL-1 30.3 (NM_171998.3: c.87_234del)
Fig. 1C
Southern Blot OR WGS N/A –
Microbiology and virology Mycoplasma Negative Data with author
Differentiation potential Embryoid body formation
(Immunofluorescence)
Endoderm: SOX17
Mesoderm: Brachyury
Ectoderm: PAX6
Fig. 1H, I
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B,
Hepatitis C
N/A –
Genotype additional info
(OPTIONAL)
Blood group genotyping N/A –
HLA tissue typing N/A –
Table 1
Summary of lines.
hESC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
SCSe001-A-1/
MCRIe002-A-1
MEL-1 10.2 Male N/A European NM_171998.3: c.82_86del Parkinson's Disease
SCSe001-A-2/
MCRIe002-A-2
MEL-1 30.3 Male N/A European NM_171998.3: c.87_234del Parkinson's Disease
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2.5. Embryoid body (EB) formation
EBs were formed by spin-aggregation. Briefly, hESC were seeded in
ultra-low adherence 96 well plates, aggregated by centrifugation and
cultured in EB medium containing E8 medium (Stemcell technologies),
0.02% Gentamicin (Gibco/Invitrogen) and 0.5% polyvinyl alcohol (PVA)
(Sigma). After 24 h, the cellswere cultured in E8medium supplemented
only with 0.02% Gentamicin, andmediumwas changed every 2 days for
3 weeks before analysis. For IF analysis, EBs were fixed with 4% PFA for
30min, then placed in a serial dilution of PBS-buffered sucrose solutions
(10, 20 and 30% respectively) at room temperature. EBs were then
embedded in Optimal cutting temperature compound (OCT),
cryosectioned at 10 µm before IF staining was carried out as described
above.
2.6. Karyotype analysis
We performed molecular karyotype analysis using the Infinium
CoreExome-24 SNP array and compared the data to the human refer-
ence sequence hg19/GRCh37 (Feb 2009). Both derived RAB39B mutant
lines (MEL-1 10.2 andMEL-1 30.3) showed a normal karyotype. To con-
firm the integrity of the clones, we performed Infinium CoreExome-24
SNP array analysis on the parental MEL-1 line. We then compared the
SNP array data from all lines the using SNPduo comparative analysis
(http://pevsnerlab.kennedykrieger.org/SNPduo/). This analysis demon-
strated that the parental andmutant lines were identical, confirming no
alterations to the genomic integrity of the mutant clones occurred dur-
ing gene editing.
2.7. Mycoplasma detection
Absence of mycoplasma contamination was confirmed by real-time
PCR by the commercial service provider Cerberus Sciences (Adelaide,
Australia).
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Table 3
Reagents details.
Antibodies used for immunocytochemistry/flow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency Marker Mouse anti-OCT4A 1:200 R and D Systems Cat# MAB17591, RRID: AB_10719296
Pluripotency Marker Mouse anti-SOX2 1:200 R and D Systems Cat# MAB2018, RRID: AB_358009
Pluripotency Marker Goat anti-NANOG 1:200 R and D Systems Cat# AF1997, RRID: AB_355097
Pluripotency Marker SSEA-4 APC 1:100 BioLegend Cat# 330408, RRID: AB_1089200
Pluripotency Marker CD9 1:20 BD Biosciences Cat# 555371, RRID: AB_395773
Pluripotency Marker CD36 (Ep-CAM) PeCy7 1:100 BioLegend Cat# 324222, RRID: AB_2561506
Differentiation Marker Goat anti-SOX17 1:200 R and D Systems Cat# AF1924, RRID: AB_355060
Differentiation Marker Goat anti-Brachyury 1:200 R and D Systems Cat# AF2085, RRID: AB_2200235
Differentiation Marker Mouse anti-PAX6 1:200 DSHB Cat# pax6, RRID:AB_528427
Secondary antibody Goat anti-Mouse IgG, Alexa Fluor 594 1:1000 Thermo Fisher Scientific Cat# A-11032, RRID: AB_2534091
Secondary antibody Donkey anti-Goat IgG, Alexa Fluor 488 1:1000 Thermo Fisher Scientific Cat# A-11055, RRID: AB_2534102
Secondary antibody Donkey anti-Goat IgG, Alexa Fluor 594 1:1000 Thermo Fisher Scientific Cat# A-11058, RRID: AB_2534105
Primers
Target Forward/Reverse primer (5′-3′)
CRISPR guide RAB39B Exon 1 5’-CTGATCCGCCGCTTCACCGA-3’
CRISPR guide RAB39B Exon 2 5’-CCATCACTCGCGCCTACTAC-3’
Genotyping and targeted mutation sequencing RAB39B Forward 5’-CTGATCCGCCGCTTCACCGA-3’
Genotyping and targeted mutation sequencing RAB39B Reverse 5’-CGAGTCACTTGCCTCTGTGT-3’
House-Keeping gene GAPDH Forward 5’-CAGCCGAGCCACATCGCTCAG-3’
House-Keeping gene GAPDH Reverse 5’-TGAGGCTGTTGTCATACTTCTC-3’
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